Published in Blood on January 09, 2008
SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res (2003) 25.86
On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 18.32
Nomenclature for the description of human sequence variations. Hum Genet (2001) 7.90
The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J (1989) 4.49
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res (2006) 2.38
Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature (1999) 1.97
The tertiary structure and domain organization of coagulation factor VIII. Blood (2007) 1.96
Bovine chymotrypsinogen A X-ray crystal structure analysis and refinement of a new crystal form at 1.8 A resolution. J Mol Biol (1985) 1.81
Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature (1999) 1.58
X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A (1995) 1.58
The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci U S A (2004) 1.44
A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood (1997) 1.37
Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet (2005) 1.29
Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood (2001) 1.26
Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII gene. Genomics (1990) 1.23
Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein. J Biol Chem (2003) 1.22
Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci U S A (1991) 1.15
Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am J Hum Genet (1996) 1.10
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. Proc Natl Acad Sci U S A (2001) 1.10
Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci U S A (1998) 1.07
New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci (2002) 1.07
Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem (2004) 1.05
Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine). Proc Natl Acad Sci U S A (1989) 1.05
Structure and dynamics of zymogen human blood coagulation factor X. Biophys J (2002) 1.05
The molecular genetic analysis of hemophilia A: a directed search strategy for the detection of point mutations in the human factor VIII gene. Blood (1990) 1.03
Somatic mosaicism in hemophilia A: a fairly common event. Am J Hum Genet (2001) 1.03
Factor VIII A3 domain residues 1954-1961 represent an A1 domain-interactive site. Biochemistry (2005) 1.02
Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem (1997) 1.02
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood (2000) 1.00
Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry (2000) 1.00
Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. J Thromb Haemost (2007) 1.00
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood (2000) 0.98
The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Thromb Haemost (2004) 0.98
Mutating factor VIII: lessons from structure to function. Blood Rev (2005) 0.98
Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. Hum Mutat (2007) 0.96
Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood (2000) 0.96
Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A. Haematologica (2005) 0.93
Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Hum Mutat (2005) 0.93
An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood (1989) 0.92
A strategy to profile prime and non-prime proteolytic substrate specificity. Bioorg Med Chem Lett (2005) 0.91
Molecular and pathological basis of aceruloplasminemia. Biol Res (2006) 0.91
The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study. Biochemistry (1996) 0.91
Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A. Br J Haematol (2000) 0.90
Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood (2001) 0.90
Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A. Genomics (1993) 0.90
Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. J Biol Chem (2004) 0.90
Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem (1997) 0.89
Start of UK confidential haemophilia A database: analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch. Haemophilia Centres. Thromb Haemost (1999) 0.88
Familial nonrandom inactivation linked to the X inactivation centre in heterozygotes manifesting haemophilia A. Eur J Hum Genet (2005) 0.87
Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein. Biochemistry (2006) 0.87
Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex. Blood Coagul Fibrinolysis (2000) 0.87
Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. Br J Haematol (1995) 0.86
Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem (2004) 0.86
Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data. Br J Haematol (2001) 0.86
The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients. Haematologica (2006) 0.85
Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. J Thromb Haemost (2004) 0.85
Analysis of 18 novel mutations in the factor VIII gene. Br J Haematol (2003) 0.84
Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A. Thromb Haemost (1994) 0.82
The identification and classification of 41 novel mutations in the factor VIII gene (F8C). Hum Mutat (2002) 0.81
Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations. Thromb Haemost (2006) 0.81
Sixteen novel hemophilia A causative mutations in the first Argentinian series of severe molecular defects. Haematologica (2007) 0.81
Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single-stranded conformation polymorphism. Blood Coagul Fibrinolysis (1994) 0.81
A directed search for mutations in hemophilia A using restriction enzyme analysis and denaturing gradient gel electrophoresis. A study of seven exons in the factor VIII gene of 170 cases. Nouv Rev Fr Hematol (1992) 0.81
Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution. Hum Mutat (2006) 0.80
Eleven novel mutations in the factor VIII gene from Brazilian hemophilia A patients. Blood (1995) 0.80
Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population. Br J Haematol (2005) 0.80
Amino acid substitutions in conserved domains of factor VIII and related proteins: study of patients with mild and moderately severe hemophilia A. Hum Mutat (1992) 0.80
Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors. Protein Eng Des Sel (2004) 0.79
Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol (2002) 0.78
Two novel mutations at 373 codon of FVIII gene detected by DGGE. Thromb Haemost (1993) 0.78
Molecular models of the procoagulant factor VIIIa-factor IXa complex. J Thromb Haemost (2005) 0.78
Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses. Thromb Haemost (2002) 0.77
Analysis of the consequences of premature termination codons within factor VIII coding sequences. J Thromb Haemost (2003) 0.77
Mutations of the factor VIII gene in thai hemophilia A patients. Hum Mutat (2000) 0.76
Seven novel and four recurrent point mutations in the factor VIII (F8C) gene. Hum Mutat (2001) 0.76
Fluorescent chemical cleavage of mismatches for efficient screening of the factor VIII gene. Hum Mutat (1998) 0.76
Three novel point mutations causing haemophilia A. Haemophilia (2002) 0.76
Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J Immunol (2009) 2.14
Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature (2003) 1.92
A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene. Hum Mutat (2003) 1.61
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat (2003) 1.54
Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol (2007) 1.49
Mutations in the NKX2-5 gene in patients with stroke and patent foramen ovale. Clin Neurol Neurosurg (2009) 1.44
Inversion of intron 1 of the factor VIII gene for direct molecular diagnosis of hemophilia A. Haematologica (2003) 1.42
Mutations in the pre-mRNA splicing-factor genes PRPF3, PRPF8, and PRPF31 in Spanish families with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci (2003) 1.40
In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med (2011) 1.38
Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol (2005) 1.34
Microarray-based mutation analysis of 183 Spanish families with Usher syndrome. Invest Ophthalmol Vis Sci (2009) 1.33
Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem (2001) 1.27
Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Hum Mol Genet (2005) 1.26
Mutation spectrum of EYS in Spanish patients with autosomal recessive retinitis pigmentosa. Hum Mutat (2010) 1.26
Microarray-based mutation analysis of the ABCA4 gene in Spanish patients with Stargardt disease: evidence of a prevalent mutated allele. Mol Vis (2006) 1.21
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res (2008) 1.20
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer (2004) 1.18
Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet (2008) 1.17
Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem (2002) 1.15
Fibrinogen substrate recognition by staphylocoagulase.(pro)thrombin complexes. J Biol Chem (2005) 1.14
Molecular basis of protein S deficiency. Thromb Haemost (2007) 1.14
Synaptic defects in type I spinal muscular atrophy in human development. J Pathol (2013) 1.13
Mutational screening of the USH2A gene in Spanish USH patients reveals 23 novel pathogenic mutations. Orphanet J Rare Dis (2011) 1.09
Spectrum of the ABCA4 gene mutations implicated in severe retinopathies in Spanish patients. Invest Ophthalmol Vis Sci (2007) 1.08
Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One (2008) 1.08
Isolation, cloning and structural characterisation of boophilin, a multifunctional Kunitz-type proteinase inhibitor from the cattle tick. PLoS One (2008) 1.06
Novel fluorescent prothrombin analogs as probes of staphylocoagulase-prothrombin interactions. J Biol Chem (2005) 1.06
Tick-derived Kunitz-type inhibitors as antihemostatic factors. Insect Biochem Mol Biol (2009) 1.03
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics (2013) 1.02
Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutations. Eur J Hum Genet (2003) 1.02
The 2.2-A crystal structure of human pro-granzyme K reveals a rigid zymogen with unusual features. J Biol Chem (2002) 1.01
Copy-number variations in EYS: a significant event in the appearance of arRP. Invest Ophthalmol Vis Sci (2011) 1.01
Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J Endotoxin Res (2007) 1.01
Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor. J Biol Chem (2004) 1.01
Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis (2010) 1.00
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms. Hum Mol Genet (2009) 0.98
The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Thromb Haemost (2004) 0.98
Correlation of genetic and clinical findings in Spanish patients with X-linked juvenile retinoschisis. Invest Ophthalmol Vis Sci (2009) 0.98
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.97
The 1.4 a crystal structure of kumamolysin: a thermostable serine-carboxyl-type proteinase. Structure (2002) 0.96
Structural basis for reduced staphylocoagulase-mediated bovine prothrombin activation. J Biol Chem (2005) 0.95
New mutations in BBS genes in small consanguineous families with Bardet-Biedl syndrome: detection of candidate regions by homozygosity mapping. Mol Vis (2010) 0.94
Three novel and the common Arg677Ter RP1 protein truncating mutations causing autosomal dominant retinitis pigmentosa in a Spanish population. BMC Med Genet (2006) 0.94
Subcellular localization and in vivo subunit interactions of ubiquitous mu-calpain. J Biol Chem (2003) 0.93
Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications. J Med Chem (2010) 0.92
Exome sequencing identifies KIAA1377 and C5orf42 as susceptibility genes for monomelic amyotrophy. Neuromuscul Disord (2012) 0.92
Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord (2011) 0.92
Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function? J Neuropathol Exp Neurol (2005) 0.92
Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol (2005) 0.91
Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer (2004) 0.91
A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics (2013) 0.91
RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain. Hum Mutat (2003) 0.91
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat (2010) 0.91
Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol (2007) 0.90
Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia. Haematologica (2003) 0.90
The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol (2009) 0.90
Should gamete donors be tested for spinal muscular atrophy? Fertil Steril (2002) 0.90
Complexity of phenotype-genotype correlations in Spanish patients with RDH12 mutations. Invest Ophthalmol Vis Sci (2008) 0.90
Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain (2002) 0.89
Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector. Proc Natl Acad Sci U S A (2012) 0.88
Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis. PLoS One (2013) 0.87
Prenatal diagnosis in myotonic dystrophy type 1. Thirteen years of experience: implications for reproductive counselling in DM1 families. Prenat Diagn (2007) 0.87
Plasminogen substrate recognition by the streptokinase-plasminogen catalytic complex is facilitated by Arg253, Lys256, and Lys257 in the streptokinase beta-domain and kringle 5 of the substrate. J Biol Chem (2009) 0.86
Purification, crystallization and preliminary crystallographic analysis of the CBS-domain pair of cyclin M2 (CNNM2). Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.86
Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability. Eur J Hum Genet (2011) 0.86
BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis (2012) 0.86
Clustering of cancer-related mutations in a subset of BRCA1 alleles: a study in the Spanish population. Int J Cancer (2002) 0.86
High frequency of CRB1 mutations as cause of Early-Onset Retinal Dystrophies in the Spanish population. Orphanet J Rare Dis (2013) 0.86
Pathophysiology of interleukin-1 receptor-associated kinase-M: implications in refractory state. Curr Opin Infect Dis (2006) 0.86
Serum soluble transferrin receptor concentrations are increased in central obesity. Results from a screening programme for hereditary hemochromatosis in men with hyperferritinemia. Clin Chim Acta (2008) 0.85
Novel mutations in the USH1C gene in Usher syndrome patients. Mol Vis (2010) 0.85
Allelic and genotypic associations of DRD2 TaqI A polymorphism with heroin dependence in Spanish subjects: a case control study. Behav Brain Funct (2007) 0.85
Molecular approach in the study of Alström syndrome: analysis of ten Spanish families. Mol Vis (2012) 0.85
Clinical and genetic findings in five female patients with haemophilia A: Identification of a novel missense mutation, p.Phe2127Ser. Thromb Haemost (2010) 0.85
A genetic polymorphism in the coding region of the gastric intrinsic factor gene (GIF) is associated with congenital intrinsic factor deficiency. Hum Mutat (2004) 0.85
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers. Breast Cancer Res Treat (2010) 0.84
Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. PLoS One (2013) 0.84
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother (2012) 0.84
Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother (2011) 0.84
Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br J Clin Pharmacol (2010) 0.84
Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys (2011) 0.84
Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. Biochemistry (2002) 0.84
Rapid identification of female haemophilia A carriers with deletions in the factor VIII gene by quantitative real-time PCR analysis. Thromb Haemost (2005) 0.84